Related Experiment Video
Updated: May 31, 2026
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Gareth J Morgan1, Dennis D Lee2, Nisha S Joseph3
1Perlmutter Cancer Center, NY Langone Health, New York, NY.
Summary
High-risk multiple myeloma (HRMM) patients face poor outcomes due to treatment resistance. Novel strategies are needed to define HRMM biology and develop personalized therapies for better survival.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- High-risk multiple myeloma (HRMM) accounts for 15%-25% of diagnoses and shows limited survival improvement despite therapeutic advances.
- HRMM presents a significant clinical challenge due to early treatment resistance and poor prognosis, with increasing prevalence at relapse.
Purpose of the Study:
- To establish a framework for understanding HRMM biology and clinical definition.
- To identify novel therapeutic strategies, including personalized approaches, to overcome adverse high-risk biology in multiple myeloma.
Main Methods:
- Reviewing evolving definitions of HRMM.
- Investigating the biological drivers of HRMM, such as 17p loss and P53 mutations.
- Exploring personalized therapeutic strategies using targeted agents and immunotherapies.
Main Results:
- Significant inroads are being made in dissecting the heterogeneous biology of HRMM beyond known drivers like 17p loss and P53 mutations.
- The study provides a framework for standardized HRMM identification and clinical trial enrollment.
Conclusions:
- A standardized approach to defining and understanding HRMM biology is crucial for improving patient outcomes.
- Personalized therapeutic strategies hold promise for overcoming the challenges posed by high-risk multiple myeloma biology.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...